Literature DB >> 31211693

Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway.

Maite Alvarez1, Federico Simonetta1, Jeanette Baker1, Antonio Pierini1, Arielle S Wenokur1, Alyssa R Morrison1, William J Murphy2, Robert S Negrin1.   

Abstract

NK cell exhaustion (NCE) due to sustained proliferation results in impaired NK cell function with loss of cytokine production and lytic activity. Using murine models of chronic NK cell stimulation, we have identified a phenotypic signature of NCE characterized by up-regulation of the terminal differentiation marker KLRG1 and by down-regulation of eomesodermin and the activating receptor NKG2D. Chronic stimulation of mice lacking NKG2D resulted in minimized NCE compared to control mice, thus identifying NKG2D as a crucial mediator of NCE. NKG2D internalization and downregulations on NK cells has been previously observed in the presence of tumor cells with high expression of NKG2D ligands (NKG2DL) due to the activation of the DNA damage repair pathways. Interestingly, our study revealed that during NK cell activation there is an increase of MULT1, and NKG2DL, that correlates with an induction of DNA damage. Treatment with the ATM DNA damage repair pathway inhibitor KU55933 (KU) during activation reduced NCE by improving expression of activation markers and genes involved in cell survival, by sustaining NKG2D expression and by preserving cell functionality. Importantly, NK cells expanded ex vivo in the presence of KU displayed increased anti-tumor efficacy in both NKG2D-dependent and -independent mouse models. Collectively, these data demonstrate that NCE is caused by DNA damage and regulated, at least in part, by NKG2D. Further, the prevention of NCE is a promising strategy to improve NK cell-based immunotherapy.

Entities:  

Keywords:  DNA repair; Immunology; Immunotherapy; NK cells; Oncology

Year:  2019        PMID: 31211693      PMCID: PMC6675585          DOI: 10.1172/jci.insight.127729

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  61 in total

1.  Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D.

Authors:  Leonidas N Carayannopoulos; Olga V Naidenko; Daved H Fremont; Wayne M Yokoyama
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

2.  Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance.

Authors:  David E Oppenheim; Scott J Roberts; Sarah L Clarke; Renata Filler; Julie M Lewis; Robert E Tigelaar; Michael Girardi; Adrian C Hayday
Journal:  Nat Immunol       Date:  2005-08-14       Impact factor: 25.606

3.  Dysregulation of signaling pathways in CD45-deficient NK cells leads to differentially regulated cytotoxicity and cytokine production.

Authors:  David G T Hesslein; Rayna Takaki; Michelle L Hermiston; Arthur Weiss; Lewis L Lanier
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-20       Impact factor: 11.205

4.  NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation.

Authors:  Nicholas D Huntington; Hy Tabarias; Kirsten Fairfax; Jason Brady; Yoshihiro Hayakawa; Mariapia A Degli-Esposti; Mark J Smyth; David M Tarlinton; Stephen L Nutt
Journal:  J Immunol       Date:  2007-04-15       Impact factor: 5.422

5.  The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor.

Authors:  Stephan Gasser; Sandra Orsulic; Eric J Brown; David H Raulet
Journal:  Nature       Date:  2005-07-03       Impact factor: 49.962

6.  Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts.

Authors:  Kouetsu Ogasawara; Jonathan Benjamin; Rayna Takaki; Joseph H Phillips; Lewis L Lanier
Journal:  Nat Immunol       Date:  2005-08-07       Impact factor: 25.606

7.  Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells.

Authors:  Jérôme D Coudert; Jacques Zimmer; Elena Tomasello; Marek Cebecauer; Marco Colonna; Eric Vivier; Werner Held
Journal:  Blood       Date:  2005-05-10       Impact factor: 22.113

8.  NKG2D blockade prevents autoimmune diabetes in NOD mice.

Authors:  Kouetsu Ogasawara; Jessica A Hamerman; Lauren R Ehrlich; Helene Bour-Jordan; Pere Santamaria; Jeffrey A Bluestone; Lewis L Lanier
Journal:  Immunity       Date:  2004-06       Impact factor: 31.745

9.  Expansion and contraction of the NK cell compartment in response to murine cytomegalovirus infection.

Authors:  Scott H Robbins; Marlowe S Tessmer; Toshifumi Mikayama; Laurent Brossay
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

10.  NK cell activation through the NKG2D ligand MULT-1 is selectively prevented by the glycoprotein encoded by mouse cytomegalovirus gene m145.

Authors:  Astrid Krmpotic; Milena Hasan; Andrea Loewendorf; Tanja Saulig; Anne Halenius; Tihana Lenac; Bojan Polic; Ivan Bubic; Anja Kriegeskorte; Ester Pernjak-Pugel; Martin Messerle; Hartmut Hengel; Dirk H Busch; Ulrich H Koszinowski; Stipan Jonjic
Journal:  J Exp Med       Date:  2005-01-10       Impact factor: 14.307

View more
  26 in total

1.  Minimal PD-1 expression in mouse and human NK cells under diverse conditions.

Authors:  Sean J Judge; Cordelia Dunai; Ethan G Aguilar; Sarah C Vick; Ian R Sturgill; Lam T Khuat; Kevin M Stoffel; Jonathan Van Dyke; Dan L Longo; Morgan A Darrow; Stephen K Anderson; Bruce R Blazar; Arta M Monjazeb; Jonathan S Serody; Robert J Canter; William J Murphy
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

2.  Down-regulation of PR/SET domain 10 underlies natural killer cell dysfunction in hepatocellular carcinoma.

Authors:  Jiantao Han; Chao Ke; Bin Jiang; Hongjian Zhou; Hanbin Xu; Xingwang Xie
Journal:  Clin Exp Immunol       Date:  2021-10-10       Impact factor: 4.330

Review 3.  Immunomodulation of NK Cells by Ionizing Radiation.

Authors:  Jiarui Chen; Xingyu Liu; Zihang Zeng; Jiali Li; Yuan Luo; Wenjie Sun; Yan Gong; Junhong Zhang; Qiuji Wu; Conghua Xie
Journal:  Front Oncol       Date:  2020-06-16       Impact factor: 6.244

Review 4.  Dichotomous Regulation of Acquired Immunity by Innate Lymphoid Cells.

Authors:  Takashi Ebihara
Journal:  Cells       Date:  2020-05-11       Impact factor: 6.600

5.  Infusion of Host-Derived Unlicensed NK Cells Improves Donor Engraftment in Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation.

Authors:  Maite Alvarez; Antonio Pierini; Federico Simonetta; Jeanette Baker; Kristina Maas-Bauer; Toshihito Hirai; Robert S Negrin
Journal:  Front Immunol       Date:  2021-01-07       Impact factor: 7.561

6.  NK Cells Negatively Regulate CD8 T Cells to Promote Immune Exhaustion and Chronic Toxoplasma gondii Infection.

Authors:  Daria L Ivanova; Ryan Krempels; Stephen L Denton; Kevin D Fettel; Giandor M Saltz; David Rach; Rida Fatima; Tiffany Mundhenke; Joshua Materi; Ildiko R Dunay; Jason P Gigley
Journal:  Front Cell Infect Microbiol       Date:  2020-07-08       Impact factor: 5.293

7.  Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.

Authors:  Maite Alvarez; Federico Simonetta; Jeanette Baker; Alyssa R Morrison; Arielle S Wenokur; Antonio Pierini; Pedro Berraondo; Robert S Negrin
Journal:  Front Immunol       Date:  2020-02-11       Impact factor: 7.561

Review 8.  Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?

Authors:  Aviad Ben-Shmuel; Guy Biber; Mira Barda-Saad
Journal:  Front Immunol       Date:  2020-02-21       Impact factor: 7.561

Review 9.  Characterizing the Dysfunctional NK Cell: Assessing the Clinical Relevance of Exhaustion, Anergy, and Senescence.

Authors:  Sean J Judge; William J Murphy; Robert J Canter
Journal:  Front Cell Infect Microbiol       Date:  2020-02-13       Impact factor: 5.293

Review 10.  Interaction between Fibroblasts and Immune Cells Following DNA Damage Induced by Ionizing Radiation.

Authors:  Kalaiyarasi Ragunathan; Nikki Lyn Esnardo Upfold; Valentyn Oksenych
Journal:  Int J Mol Sci       Date:  2020-11-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.